KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Position Lifted by Tang Capital Management LLC

Tang Capital Management LLC boosted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 13.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,893,847 shares of the specialty pharmaceutical company's stock after purchasing an additional 572,300 shares during the quarter. KalVista Pharmaceuticals makes up approximately 2.7% of Tang Capital Management LLC's holdings, making the stock its 8th biggest position. Tang Capital Management LLC owned 9.90% of KalVista Pharmaceuticals worth $41,451,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Aquatic Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth $44,000. Tower Research Capital LLC TRC lifted its position in KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after purchasing an additional 5,502 shares during the last quarter. Legal & General Group Plc grew its stake in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after buying an additional 1,494 shares in the last quarter. Martin Worley Group bought a new stake in shares of KalVista Pharmaceuticals in the 4th quarter worth about $86,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after buying an additional 2,043 shares in the last quarter.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV traded up $0.22 on Friday, hitting $11.64. 84,095 shares of the company's stock were exchanged, compared to its average volume of 421,003. The business's 50 day simple moving average is $11.97 and its two-hundred day simple moving average is $10.45. The stock has a market capitalization of $578.69 million, a price-to-earnings ratio of -3.18 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the transaction, the insider now directly owns 106,611 shares in the company, valued at $1,262,274.24. This represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were acquired at an average cost of $9.42 per share, for a total transaction of $235,500.00. Following the transaction, the insider now directly owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. This trade represents a 0.47% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 15,647 shares of company stock valued at $181,770. 10.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on KALV shares. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. Needham & Company LLC restated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Jones Trading reaffirmed a "buy" rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $24.83.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).